Abstract:Objective: To investigate the effect of calcium-independent phospholipase A(2) (iPLA(2)) inhibitor in reducing hepatocyte lipoapoptosis and improving insulin resistance. Methods: A total of 28 male Sprague-Dawley rats were randomly divided into the following three groups: 12 rats in group I (normal control group) were given normal diet for 18 weeks; 8 rats in group II (non-alcoholic fatty liver disease model group) were given high-fat diet for 18 weeks; 8 rats in group III (iPLA(2) inhibitor group) were given high-fat diet for 18 weeks and intraperitoneal injection of the iPLA(2) inhibitor bromoenol lactone 150 μg/kg once every other day since week 15 (14 times of injection in total). All the rats were sacrificed at the same time, and body weight and liver weight were measured. Blood lipids, serum enzymes, fasting blood glucose, fasting insulin, free fatty acid, and serum iPLA(2) concentration were measured in each group, and liver pathological changes were evaluated. The terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling was used to measure the level of hepatocyte apoptosis and the apoptotic index was calculated. Quantitative PCR was used to measure the mRNA expression of iPLA(2). The Student-Newman-Keuls test and the chi-square test were used for comparison of parameters between groups I, II, and III. P < 0.05 was considered statistically significant. Results: Compared with group I, group II had significant increases in triglyceride (0.75±0.05 mmol/L vs 1.20±0.13 mmol/L, P < 0.05), cholesterol (1.50±0.12 mmol/L vs 2.94±0.34 mmol/L, P < 0.05), low-density lipoprotein (0.65±0.06 mmol/L vs 1.30±0.16 mmol/L, P < 0.05), free fatty acid (0.58±0.09 mEq/L vs 0.80±0.20 mEq/L, P < 0.05), fasting blood glucose (4.85±0.22 mmol/L vs 6.94±0.65 mmol/L, P < 0.05), and fasting insulin (0.89±0.52 mmol/L vs 1.29±0.52 mmol/L, P < 0.05), and a significant reduction in the insulin sensitivity index (0.52±0.21 vs 0.27±0.11, P < 0.05); group II also had significant inflammation and fatty degeneration shown by liver pathology, and compared with group I, group II had significant increases in apoptotic cells and apoptotic index (0.58%±0.17% vs 39.69%±4.96%, P < 0.05). Compared with group I, group II had significant increases in serum iPLA(2) concentration (2.92±0.08 ng/ml vs 3.28±0.14 ng/ml, P < 0.05) and the mRNA expression of iPLA(2) in the liver (1.07±0.18 vs 7.68±0.49, P < 0.05). Compared with group II, group III had a lower level of hepatocyte apoptosis, a significant reduction in apoptotic index (39.69%±4.96% vs 24.80%±2.53%, P < 0.05), significant reductions in serum iPLA(2) concentration (3.28±0.14 ng/ml vs 2.64±0.24 ng/ml, P < 0.05) and the mRNA expression of iPLA(2) in the liver (7.68±0.49 vs 2.60±0.36, P < 0.05), significant reductions in fasting insulin (1.29±0.52 mmol/L vs 0.80±0.09 mmol/L, P < 0.05) and fasting blood glucose (6.94±0.65 mmol/L vs 5.18±0.35 mmol/L, P < 0.05), and a significant increase in insulin sensitivity index (0.27±0.11 vs 0.45±0.09, P < 0.05). Conclusion: There is a significant increase in the expression of iPLA(2) in rats with non-alcoholic fatty liver disease, and iPLA2 inhibitor can reduce hepatocyte lipoapoptosis and improve insulin resistance.

Effect of Modified Didang Decoction on PAI-1 Gene Expression in Liver in Insulin Resistance Rats

Effect of Modified Didang Decoction on T-Pa,pai-1 and PAl-1 Gene Express in Fat in InsuIin Resistance Rats

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

[Effect of Calcium-Independent Phospholipase A(2) Inhibitor in Reducing Hepatocyte Lipoapoptosis and Improving Insulin Resistance].

Research on the Protection Effect of Pioglitazone for Non-Alcoholic Fatty Liver Disease (NAFLD) in Rats

[Preventive Effects of Pioglitazone on Rat Fatty Liver Induced by a High Fat Diet].

Effects of “xiaogao Zhuanzhuo Decoction” on Lipid Peroxidation and Insulin Resistance in Rats of Obese Non-alcoholic Fatty Liver

The effect of Liuwei Dihuang decoction on PI3K/Akt signaling pathway in liver of type 2 diabetes mellitus (T2DM) rats with insulin resistance

Effect of Tangzhiping on Serum Adiponectin Level and the mRNA Expression of Adiponectin in Epididymal Fat Pads in Rats with insulin Resistance

Effects of Tangzhiping on Glucose and Lipid Metabolism in Insulin-Resistance Rat Model

The Effect of Tangzhiping on Glycemic and Lipid Metabolism and Insulin Sensitivity in Rat Insulin Resistance Model

Effects of Modified Sanzi Yangqin Decoction on Tyrosine Phosphorylation of IRS-1 in Skeletal Muscle of Type 2 Diabetic Rats

Insulin Treatment Can Improve Hepatic Lipid Accumulation in Rats with Type 2 Diabetes Through Adiponectin Receptor 2/peroxisome Proliferator-Activated Receptor-Α Signaling Pathway

Expression of Plasminogen Activator Inhibitor-1 in Kidney of Diabetic Rats and Its Modulation by Tongxinluo Capsule

Ang-(1-7) Improves Islet B Cell Function By Up-Regulating The Activity Of Ang-(1-7)-Mas Axis/Pdx-1

Inhibitory Effect of Pioglitazone on TGF-β1 Gene Expression in Renal Cortex of Diabetic Rats

Effects of shenqi decoction on the gene expression of endothelins in rats with myocardial ischemia

Effect of Tangzhiping on Serum TNF-α Level and mRNA Expression of TNF-α in Epididymal Fat Pads in Rats with Insulin Resistance

Impacts of Tangzhiping on AMPK/PGC - 1α Signaling Pathway in the Rats of Insulin Resistance

Impacts of Tangzhiping on Genetic Expressions of PGC - 1α,Cytochrome C and ATP Synthases β Subunit in the Rats of Insulin Resistance

Effects of Tangzhiping on oxidative stress in rat insulin resistance model